[Earnings Alert ] 9 Potentially High Upside Reporting Monday

This is a must read View this email [in your browser]( [dmm-editor] [Will there be War with China?]( The U.S., China and Russia are rushing to build a strange new weapon. At the center of this new arms race is a small company from Alabama. [Our research proves that anyone who gets in now could profit 8990% ]( [Read More >>]( August 7, 2021 (Earnings Announcements for Monday, August 9th) Dear Reader, We have identified several interesting companies that are expected to release earnings very soon. Analysts seem to like these companies and we think you may be interested too. Some of these companies may breakout to the upside or breakdown if their earnings news is not as expected. You need to keep an eye out just in case. We are inviting you to take a look at the following 9 companies along with their upcoming earnings Monday, August 9th. Keep in mind, these companies are all expected to announce their earnings Monday, but they may be subject to change. Reporting Before Open, Monday, August 9th (subject to change) ========================= [Avadel Pharmaceuticals (AVDL)]( Earnings Date: Monday, August 9th, Earnings Release Time: Pre-Market Sector: Healthcare Summary: Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. - Last Price: $7.9 - Price Change: ($0.32) (4.22%) - Yearly Gain: -10.61% - Price Target: $19.67 (148.99%) - Market Cap: $462.05M - PE Ration: n/a Here are 3rd party ratings for AVDL: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term - Barchart.com: Hold Last Analyst Action: Oren Livnat, analyst at H.C. Wainwright, reiterates coverage on Avadel Pharmaceuticals (AVDL) with a Buy rating and has set a price target of $17. What is the sentiment on the street regarding Avadel Pharmaceuticals? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Neutral - Blogger Consensus: Bullish - Media Buzz: Medium - Insider Signal: No Signal - Investor Sentiment: Very Positive - Hedge Fund signal: Neutral ========================= [Axsome Therapeutics (AXSM)]( Earnings Date: Monday, August 9th, Earnings Release Time: Pre-Market Sector: Healthcare Summary: Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. - Last Price: $51.16 - Price Change: ($0.5) (0.99%) - Yearly Gain: -35.08% - Price Target: $135.33 (164.52%) - Market Cap: $1.92B - PE Ration: n/a Here are 3rd party ratings for AXSM: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term - Barchart.com: Strong Sell Last Analyst Action: Vikram Purohit, analyst at Morgan Stanley, reiterates coverage on Axsome Therapeutics (AXSM) with a Buy rating and has set a price target of $105. What is the sentiment on the street regarding Axsome Therapeutics? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Neutral - Blogger Consensus: Bullish - Media Buzz: Very Low - Insider Signal: Positive - Investor Sentiment: Very Negative - Hedge Fund signal: Neutral ========================= [Cara Therapeutics (CARA)]( Earnings Date: Monday, August 9th, Earnings Release Time: Pre-Market Sector: Healthcare Summary: Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. - Last Price: $12.78 - Price Change: ($0.28) (2.24%) - Yearly Gain: -26.38% - Price Target: $25.75 (101.49%) - Market Cap: $639.66M - PE Ration: 35 Here are 3rd party ratings for CARA: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term - Barchart.com: Strong Sell Last Analyst Action: Jessica Fye, analyst at J.P. Morgan, reiterates coverage on Cara Therapeutics (CARA) with a Hold rating and has set a price target of $16. What is the sentiment on the street regarding Cara Therapeutics? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Very Bullish - Blogger Consensus: Bullish - Media Buzz: Medium - Insider Signal: No Signal - Investor Sentiment: Very Negative - Hedge Fund signal: Neutral ========================= [$500/week with options - here's how]( Start trading options with zero experience…but, can you even trade without risking your own money to start? There's a shortcut I have found. Here's a way not to spend a penny on options (but still trade them). This isn't a gimmick, nor are you simulating trades. You can make actual money trading options without risking a penny. So, if you are interested in options, but worried about loosing money, this is a no-brainer way to start trading options with $0. [Click here to see how to start trading.]( [Read More >>]( ========================= [Epizyme (EPZM)]( Earnings Date: Monday, August 9th, Earnings Release Time: Pre-Market Sector: Healthcare Summary: Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. - Last Price: $6.47 - Price Change: ($-0.12) (-1.82%) - Yearly Gain: -48.68% - Price Target: $26 (301.85%) - Market Cap: $659.78M - PE Ration: n/a Here are 3rd party ratings for EPZM: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term - Barchart.com: Strong Sell Last Analyst Action: Simon Yarmak, analyst at Stifel Nicolaus, reiterates coverage on Epizyme (EPZM) with a Hold rating and has set a price target of $55. What is the sentiment on the street regarding Epizyme? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Very Bullish - Blogger Consensus: Bullish - Media Buzz: Medium - Insider Signal: No Signal - Investor Sentiment: Very Negative - Hedge Fund signal: Neutral ========================= [Village Farms International (VFF)]( Earnings Date: Monday, August 9th, Earnings Release Time: Pre-Market Sector: Basic Materials Summary: Village Farms International Inc. is a producer, marketer and distributor of greenhouse-grown tomatoes, bell peppers and cucumbers primarily in North America. - Last Price: $9.91 - Price Change: ($0.03) (0.30%) - Yearly Gain: 61.97% - Price Target: $18.31 (84.76%) - Market Cap: $805.15M - PE Ration: n/a Here are 3rd party ratings for VFF: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term - Barchart.com: Strong Sell Last Analyst Action: Scott Fortune, analyst at Roth Capital, reiterates coverage on Village Farms International (VFF) with a Buy rating and has set a price target of $18. What is the sentiment on the street regarding Village Farms International? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Very Bullish - Blogger Consensus: Bullish - Media Buzz: Medium - Insider Signal: Negative - Investor Sentiment: Very Negative - Hedge Fund signal: No Signal ======================= [Bonanza Creek (BCEI)]( Earnings Date: Monday, August 9th, Earnings Release Time: After Close Sector: Utilities Summary: Bonanza Creek Energy, Inc. is engaged in the acquisition, exploration and development of onshore oil and natural gas properties in the United States. - Last Price: $37.8 - Price Change: ($0.75) (2.02%) - Yearly Gain: 88.26% - Price Target: $60.75 (60.71%) - Market Cap: $1.17B - PE Ration: 31 Here are 3rd party ratings for BCEI: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term - Barchart.com: Weak Buy Last Analyst Action: Neal Dingmann, analyst at Truist Financial, reiterates coverage on Bonanza Creek (BCEI) with a Buy rating and has set a price target of $60. What is the sentiment on the street regarding Bonanza Creek? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Neutral - Blogger Consensus: Bullish - Media Buzz: Medium - Insider Signal: Negative - Investor Sentiment: Very Negative - Hedge Fund signal: Positive ========================= [Buy this fund NOW for rock-steady dividends up to 8%... paid monthly!]( One of my absolute favorite income plays in this overpriced market is the brainchild of one of the smartest investment managers alive. It dishes out an incredible 8% dividend today (paid monthly!) and it's set up for 10%+ capital gains in the months ahead ... no matter which way the broader market swings. In fact, I like this fund so much that I've made it a cornerstone of my "7% Monthly Payer" portfolio, a simple collection of high yielders that could hand you $3,000+ every single month! [Click here for instant access to all the profitable details.]( [Read More >>]( ========================= [Celcuity (CELC)]( Earnings Date: Monday, August 9th, Earnings Release Time: After Close Sector: Services Summary: Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. - Last Price: $20.85 - Price Change: ($-0.14) (-0.67%) - Yearly Gain: 260.65% - Price Target: $40 (91.85%) - Market Cap: $310.60M - PE Ration: -21.1 Here are 3rd party ratings for CELC: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term - Barchart.com: Weak Buy Last Analyst Action: Chad Messer, analyst at Needham, reiterates coverage on Celcuity (CELC) with a Buy rating and has set a price target of $50. What is the sentiment on the street regarding Celcuity? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Neutral - Blogger Consensus: No Signal - Media Buzz: Very Low - Insider Signal: No Signal - Investor Sentiment: Very Negative - Hedge Fund signal: No Signal ========================= [Reata Pharmaceuticals (RETA)]( Earnings Date: Monday, August 9th, Earnings Release Time: After Close Sector: Healthcare Summary: Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, - Last Price: $124.29 - Price Change: ($-5.27) (-4.07%) - Yearly Gain: -14.71% - Price Target: $211.8 (70.41%) - Market Cap: $4.51B - PE Ration: n/a Here are 3rd party ratings for RETA: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term - Barchart.com: Weak Buy Last Analyst Action: Elyse Greenspan, analyst at Wells Fargo, reiterates coverage on Reata Pharmaceuticals (RETA) with a Buy rating and has set a price target of $310. What is the sentiment on the street regarding Reata Pharmaceuticals? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Neutral - Blogger Consensus: Bullish - Media Buzz: Very Low - Insider Signal: Negative - Investor Sentiment: Very Negative - Hedge Fund signal: Very Positive ========================= [Syndax Pharmaceuticals (SNDX)]( Earnings Date: Monday, August 9th, Earnings Release Time: After Close Sector: Healthcare Summary: Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. - Last Price: $14.31 - Price Change: ($0.11) (0.77%) - Yearly Gain: -5.33% - Price Target: $26.75 (86.93%) - Market Cap: $690.44M - PE Ration: n/a Here are 3rd party ratings for SNDX: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term - Barchart.com: Strong Sell Last Analyst Action: Joel Beatty, analyst at Robert W. Baird, reiterates coverage on Syndax Pharmaceuticals (SNDX) with a Buy rating and has set a price target of $31. What is the sentiment on the street regarding Syndax Pharmaceuticals? (Current ratings compiled by [TipRanks.com]() - News Sentiment: Neutral - Blogger Consensus: No Signal - Media Buzz: Very Low - Insider Signal: No Signal - Investor Sentiment: Very Negative - Hedge Fund signal: Positive ========================= [Join TipRanks.com to get all the Strong Buys, Inside Trades and more](... To your financial future! The Editor, DailyMarketMovers.com [Media Calls This A “Baby Boomer Hobby”... I Call It A Payday.]( Its widespread adoption has Reuters calling this “odd” type of trade the “new Baby Boomer hobby” ...but Jim Fink’s “twist” on this trade could hand you $1,295 on average each week from just 9 minutes of “work.” Get the inside scoop on this “$1,295 per week” system in a ground-breaking new presentation... [Click here for instant access.]( [Read More >>]( Newsletter DisclaimerThis newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Daily Market Movers PO Box 407 Mt. Mourne, North Carolina 28123 United State [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software